Literature DB >> 35805065

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830.

Ken Kudura1, Florentia Dimitriou2, Lucas Basler3, Robert Förster4, Daniela Mihic-Probst5, Tim Kutzker6, Reinhard Dummer2, Joanna Mangana2, Irene A Burger1,7, Michael C Kreissl8.   

Abstract

The authors wish to make the following corrections to this paper [...].

Entities:  

Year:  2022        PMID: 35805065      PMCID: PMC9265328          DOI: 10.3390/cancers14133268

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.575


The authors wish to make the following corrections to this paper [1]: Add a citation in the Introduction section In the original publication, the publication from Lucas Basler et al. [2] was not cited. The citation has now been inserted in the Introduction as reference [9]: In order to predict the response to immunotherapy several outcome predictive biomarkers based on the histopathology of the primary tumor (i.e., tumor thickness, ulceration, mitotic rate) [8], standard blood samples (i.e., lactate dehydrogenase LDH, calcium-binding protein B S100B) [9] or clinical aspects (i.e., sentinel lymph node involvement, anatomical site of primary tumor, gender or age) [10] have been already discussed in the literature.” Ethical approval information needs to be updated: The official and correct reference of the stated ethical approval is KEK-ZH-Nr: 2014-0193. The correct statement is as below: Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Cantonal Ethics Committee of the Canton Zurich in Switzerland (protocol code KEK-ZH-Nr: 2014-0193) on 15 March 2017. 2.1. Patient Cohort (…). All included patients consented the use of their clinical data for research purposes. This study was approved by the local ethics committee (protocol code KEK-ZH-Nr: 2014-0193) and conducted in compliance with Good Clinical Practice GCP-rules and the Declaration of Helsinki. Missing Funding In the original publication, the funder Cancer Research Center, Comprehensive Center Zurich, University Hospital Zurich (CRC_13) was not included. The correct statement is as: Funding: This research was funded by the Iten-Kohaut-Foundation (IA USZF27071) and the Cancer Research Center, Comprehensive Center Zurich, University Hospital Zurich (CRC_13). The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.
  2 in total

1.  Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.

Authors:  Matthias Guckenberger; Mitchell P Levesque; Lucas Basler; Hubert S Gabryś; Sabrina A Hogan; Matea Pavic; Marta Bogowicz; Diem Vuong; Stephanie Tanadini-Lang; Robert Förster; Ken Kudura; Martin W Huellner; Reinhard Dummer
Journal:  Clin Cancer Res       Date:  2020-04-06       Impact factor: 12.531

2.  Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830.

Authors:  Ken Kudura; Florentia Dimitriou; Lucas Basler; Robert Förster; Daniela Mihic-Probst; Tim Kutzker; Reinhard Dummer; Joanna Mangana; Irene A Burger; Michael C Kreissl
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

  2 in total
  1 in total

1.  Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830.

Authors:  Ken Kudura; Florentia Dimitriou; Lucas Basler; Robert Förster; Daniela Mihic-Probst; Tim Kutzker; Reinhard Dummer; Joanna Mangana; Irene A Burger; Michael C Kreissl
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.